GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
- Conditions
- Healthy Volunteers
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04274075
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- Conditions
- Muscular Atrophy, Spinal
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT04256265
- Locations
- 🇺🇸
Arkansas Children's Hospital; Pediatrics, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04250155
- Locations
- 🇧🇪
GasthuisZusters Antwerpen, Wilrijk, Antwerp, Belgium
🇮🇹Istituto Clinico Humanitas, Rozzano, Lombardia, Italy
🇰🇷Severance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04195958
- Locations
- 🇺🇸
Swedish Health Services, Seattle, Washington, United States
🇺🇸Broward Research Center, Pembroke Pines, Florida, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Prospective Clinicogenomic Program
- Conditions
- Small-Cell Lung Cancer (SCLC)Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Other: Blood Draw
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 945
- Registration Number
- NCT04180176
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04171765
- Locations
- 🇺🇸
National Research Inst., Los Angeles, California, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
- Conditions
- Asthma
- Interventions
- Drug: MTPS9579ADrug: Placebo
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT04092582
- Locations
- 🇺🇸
Florida Ctr-Allergy & Asthma, Miami, Florida, United States
🇵🇱ALL-MED Specjalistyczna Opieka Medyczna, Wroclaw, Poland
🇺🇸Kern Research, Bakersfield, California, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04045028
- Locations
- 🇺🇸
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇺🇸University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Macular Degeneration, Age-RelatedGeographic Atrophy
- Interventions
- Drug: Sham Control
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT03972709
- Locations
- 🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸Associated Retinal Consultants PC, Royal Oak, Michigan, United States
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03961100
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom